Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN

NCT06994845 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Immunoglobulin A Nephropathy (IgAN)

Interventions

DRUG: iptacopan

Sponsor

Novartis Pharmaceuticals